BAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Baxter International Inc (BAX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the stock has shown some positive price movement recently, the overall financial performance, analyst sentiment, and lack of strong proprietary trading signals suggest a cautious approach. Holding the stock or waiting for clearer signals might be more prudent.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI at 78.876 is approaching overbought territory, suggesting limited upside potential in the short term. The stock is trading near resistance levels (R1: 17.964, R2: 18.406), which could limit further gains.
Baxter recently unveiled innovative surgical products like the AAT XR spine surgical table and Dynamo Series smart stretcher, which could enhance operational efficiency and patient care. Revenue increased by 8.03% YoY in Q4 2025, showing some growth in sales.
The company's financials show significant challenges, including a net income loss of -$1.128 billion and a gross margin drop of -45.16% YoY. Analyst sentiment is mixed to negative, with multiple firms lowering price targets and expressing concerns about margin pressures and limited near-term visibility. Additionally, no significant hedge fund or insider trading trends have been observed, indicating a lack of strong institutional confidence.
In Q4 2025, Baxter's revenue grew by 8.03% YoY to $2.97 billion. However, the company posted a net loss of -$1.128 billion, with EPS at -2.2. Gross margin dropped significantly by -45.16% YoY, reflecting operational challenges.
Analyst sentiment is mixed to negative. Recent price target reductions include Evercore ISI lowering to $22, Citi to $19, and Goldman Sachs to $17. Analysts highlight margin pressures, underwhelming 2026 guidance, and limited near-term visibility as key concerns.
